New Drug Program Overview
Mindset is focused on developing novel IP and has developed a leading pipeline of pre-clinical psychedelic drug candidates derived from several differentiated patents describing a diversity of chemical structures optimized for pharmaceutical use
Family 1: Psilocybin-like prodrugs, substituted and deuterated analogs
- Similar receptor binding and function profile to psilocybin
- Orally active CNS penetrant
- Lead Compound MSP-1014 selected
Family 2: Next-generation psilocybin optimized for in clinic setting
- Improved receptor binding and function profile compared to psilocybin
- Shorter acting, orally active CNS penetrant
Family 3: Next-generation psilocybin optimized for microdosing
- Similar receptor binding and function profile to psilocybin
- Long Duration of effect
Family 4: DMT/ 5-meO-DMT-inspired candidates
- Currently performing in vitro screening
